Skip to main content
Clinical Trials/NCT06426953
NCT06426953RecruitingNot Applicable

Predictive Effect of TGF-β Combined With INS-PI3K-AKT Signaling Pathway Related Proteins (ADNP, MAP6, Pgc-1α) for POD in Diabetes Patients

Xie Kangjie2 sites in 1 country180 target enrollmentStarted: May 20, 2024Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
180
Locations
2
Primary Endpoint
The correlation between preoperative plasma levels of TGF-β, ADNP, MAP6, PGC-1α and the incidence of delirium within 3 days after operation was analyzed.

Study Overview

Brief Summary

To investigate the relationship between POD, TGF-β and INS-PI3K-AKT signaling pathway related proteins (ADNP, MAP6, PGC-1α) in diabetic patients

Detailed Description

The study was a two-center, prospective,single blind (blinded to subjects and evaluators),control, observational clinical study. Participants will collect 3 milliliters of blood from enrolled patients before surgery begins. The collected blood samples were processed and stored in -80℃ refrigerator. All samples were tested TGF-β and INS-PI3K-AKT signaling pathway related proteins (ADNP, MAP6, PGC-1α) by ELISA.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Prospective

Eligibility Criteria

Ages
65 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥65 years
  • History of diabetes ≥2 years and Glycated hemoglobin ≥6.5% or no history of diabetes and normal blood glucose
  • The ASA rating is Class I to III
  • The elderly patients of limited thoracic and abdominal tumor surgery

Exclusion Criteria

  • Refused to participate
  • Previous history of schizophrenia, epilepsy, Parkinson's disease
  • History of alcohol abuse or drug dependence
  • Patients with ASA grade IV and above
  • Severe visual or hearing impairment, can not cooperate with the completion of cognitive function tests
  • Participants in other clinical trials within the last two months
  • Patients with severe arrhythmia or cardiac dysfunction(EF<40%)
  • There was a clear history of neurological and psychiatric problems or long-term use of sedatives or antidepressants
  • History of cerebrovascular disease or brain surgery or trauma
  • Severe liver dysfunction (Child-Pugh class C) or severe renal dysfunction (requiring dialysis)

Outcomes

Primary Outcomes

The correlation between preoperative plasma levels of TGF-β, ADNP, MAP6, PGC-1α and the incidence of delirium within 3 days after operation was analyzed.

Time Frame: 2024-05 to 2026-06

Postoperative delirium (POD) was assessed using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) and the 3-Minute Diagnostic Interview for Confusion Assessment Method-Defined Delirium (3D-CAM). Transforming growth factor-beta (TGF-β), activity-dependent neuroprotective protein (ADNP), microtubule-associated protein 6 (MAP6), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) levels were measured using enzyme-linked immunosorbent assay (ELISA) kits.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Xie Kangjie
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Xie Kangjie

Clinical Professor

Zhejiang Cancer Hospital

Study Sites (2)

Loading locations...

Similar Trials